Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on October 29
RAMAT GAN, Israel , Oct. 07, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company...
Cancer
Terry Lynch Joins BioNxt as Capital Markets Advisor
VANCOUVER, BC / ACCESSWIRE / October 7, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT) is pleased...
OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million
-- OnKure is focused on advancing a pipeline of candidates targeting oncogenic mutations in phosphoinositide 3-kinase alpha (PI3Kα), initially in...
Bone Health and Osteoporosis Foundation (BHOF) Awarded Multi-Year Grant to Increase Bone Health Awareness from the Centers for Disease Control and Prevention (CDC)
ARLINGTON, Va., Oct. 4, 2024 /PRNewswire/ -- The Bone Health and Osteoporosis Foundation announced that it has been awarded a major...
CytoDyn Engages Syneos Health as CRO For Its Phase II Oncology Trial
VANCOUVER, Washington, Oct. 04, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab,...
Biodexa Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent Glioblastoma
October 4, 2024 Biodexa Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent...
Poseida Therapeutics Named to Newsweek’s List of the Top 200 America’s Most Loved Workplaces for 2024
Inclusion on list recognizes Poseida for employee sentiment and satisfaction SAN DIEGO, Oct. 3, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq:...
Steady Growth for ONCare Alliance With the Addition of Two New Practices in Nebraska and Illinois
Opportunities for Collaboration Continue to Draw Independent Large and Small Practices From Across the CountryPUYALLUP, WA / ACCESSWIRE / October...
The Largest Network of Research Sites Vetted to Execute Complexities of Cell & Gene Therapy (CGT) Trials Now Includes 1,500 Sites
Advarra's Gene Therapy Ready (GTR) global site network expands to better support and accelerate the rapidly growing number of CGT...
Dr. Robert Mignone of Penn Medicine Becker ENT & Allergy Selected as the First Aerin Medical Center of Excellence Provider for VivAer in NJ
Dr. Mignone's expert ENT approach brings innovative VivAer® nasal relief to New Jersey residents.ROBBINSVILLE, NJ / ACCESSWIRE / October 3,...
AIM ImmunoTech Granted U.S. Patent for Ampligen® for the Treatment of Endometriosis
Robert Edwards, MD, UPMC, Magee-Womens Hospital Robert Edwards, MD, UPMC, Magee-Womens Hospital Thomas Equels, CEO of AIM ImmunoTech Inc Thomas...
Recent clinical data confirms significantly improved predictive power of Evaxion’s AI-Immunology™ platform
Improved precision of the AI-Immunology™ platform in predicting clinically relevant vaccine targets boosts the potential of its AI-derived vaccine candidates...
Allarity Therapeutics Strengthens Leadership with Key Appointments to Accelerate Stenoparib PARP Inhibitor Program
Former Eli Lilly Research Fellow Jeremy R. Graff, Ph.D., appointed as President and Chief Development Officer to lead the Company’s clinical...
iCAD Highlights Global Availability of ProFound Cloud and International Expansion Milestones at JFR 2024
NASHUA, N.H. and PARIS, Oct. 03, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) (“iCAD” or the “Company”) a global leader...
Theriva™ Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (DSMC) Review in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients
DSMC has reviewed the safety and pharmacokinetic data from Cohort 2 and recommended that the study proceed to enroll patients...
GigaGen Awarded U.S. BARDA Contract to Develop Recombinant Polyclonal Antibody Therapies for Botulinum Neurotoxins and an Additional Biothreat
The contract will provide an initial commitment of $19.6 million and up to $135.2 million over a six-year period, supporting...
Immutep Completes Patient Enrolment in Randomised Phase II of AIPAC-003 Trial in Metastatic Breast Cancer
Media Release SYDNEY, AUSTRALIA, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”),...
Lisata Therapeutics to Participate in Upcoming October 2024 Industry and Investor Events
BASKING RIDGE, N.J., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage...
Nusano Adds to Executive Leadership Team in Advance of 2025 Commercialization
VALENCIA, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Nusano, Inc., a physics company transforming the production of medical radioisotopes, today...
Cancer centers launch Cancer AI Alliance to unlock discoveries, transform care using cancer data and applied AI
AWS, Deloitte, Microsoft and NVIDIA bring the latest in AI technology, coordination, and compute to the alliance and back with...